NGM Biopharma Raises $51 Million
NGM Biopharmaceuticals Inc., a South San Francisco-based drug startup focused on metabolic diseases, has secured the first tranche of a $51 million Series B funding round. Backers include The Column Group, Tichenor Ventures, Prospect Venture Partners and Rho Ventures. The company previously raised $25.55 million.
15 March 2010•2 mins read
